Nami Okamoto

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study.

Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study.

Journal: Modern rheumatology

Published: February 13, 2026

Comparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan.

Comparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan.

Journal: Pediatric rheumatology online journal

Published: June 19, 2025

TeMPRA: advancing continuing professional development in pediatric rheumatology in Japan.

TeMPRA: advancing continuing professional development in pediatric rheumatology in Japan.

Journal: Pediatric rheumatology online journal

Published: May 16, 2025

Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study.

Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study.

Journal: Modern rheumatology

Published: December 18, 2024

Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or polyarthritis - secondary publication.

Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or polyarthritis - secondary publication.

Journal: Modern rheumatology

Published: October 21, 2024

Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study.

Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study.

Journal: Modern rheumatology

Published: March 04, 2024

Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review.

Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review.

Journal: Modern rheumatology

Published: February 05, 2024

Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review.

Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review.

Journal: Modern rheumatology

Published: February 05, 2024

Survey of diversity awareness and environment among members of the Pediatric Rheumatology Association of Japan.

Survey of diversity awareness and environment among members of the Pediatric Rheumatology Association of Japan.

Journal: Pediatrics international : official journal of the Japan Pediatric Society

Published: April 07, 2023

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.

Journal: Lancet (London, England)

Published: October 26, 2022

Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan.

Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan.

Journal: International journal of rheumatic diseases

Published: September 02, 2022

Epidemiology conduction of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan.

Epidemiology conduction of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan.

Journal: Modern rheumatology

Published: July 05, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026